Tags : Immunic

Insights+: COVID-19 Healthcare News Monthly Updates – November 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in

Shots: The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries, 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions […]Read More

Immunic Exercises its Worldwide Exclusive Option to License for IMU-856

Shots: Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan Additionally, the option includes patent […]Read More